A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Ligelizumab (Primary) ; Ciclosporin
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 01 Oct 2023 Results assessing the safety and efficacy of ligelizumab versus placebo in adult patients with moderate-to-severe Atopic Dermatitis, published in the Journal of Investigative Dermatology.
- 31 Oct 2014 New trial record